NewEast Biosciences 是开发突变Oncogene抗体的先驱, 并拥有用于Oncogene研究较完整的抗体系列。该系列仅与突变的Oncogene结合，而不与相应的野生型结合。这些抗体可以 用于研究突变的Oncogene在肿瘤组织中的分布。因此在临床上，可以给癌患者提供指导疗法。

背景介绍：
异柠檬酸脱氢酶(IDH)催化异柠檬酸氧化脱羧生成2-羟戊二酸。异柠檬酸和苹果酸异丙酯脱氢酶家族有三个成员，IDH1, IDH2和IDH3。IDH2在中间代谢和能量产生中发挥作用。IDH2缺陷是d -2-羟戊二酸尿2型(D2HGA2)的原因。该蛋白的体细胞镶嵌突变也被发现与Ollier病和Maffucci综合征相关，R172K IDH2突变确实存在于弥漫性浸润性胶质瘤中。

免疫原：
一种来自IDH2内部区域的合成肽，其中包括人类来源的R172K突变

储存条件：储存在-20°C。避免反复冻融

蛋白质印迹:

Western blot analysis of recombinant IDH2(R172K) and wildtype proteins.Purified His-tagged IDH2(R172K) (lane 2) and wildtype protein (lane 1) were blotted with Anti-IDH2(R172K) monoclonal antibody (Cat. #26163).
免疫荧光:


Immunofluorescence of cells expressing IDH2 proteins with Anti-IDH2(R172K) antibody.HEK293T cells were transfected with pCDNA3-GFP- IDH2(R172K) plasmid , pCDNA3-GFP- IDH2 (WT) plasmid, pCDNA3-GFP- IDH2 (R172H) plasmid , pCDNA3-GFP- IDH2 (R172W) plasmid, pCDNA3-GFP- IDH2 (R172G) plasmid,pCDNA3-GFP- IDH2 (R172M) plasmid or pCDNA3-GFP- IDH2 (R172S) plasmid, then fixed and stained with anti- IDH2(R172K) monoclonal antibody (Cat. #26163).